RE:RE:Inflation Reduction Act (IRA) boosts biological drugs April 11, 2024 - " Several factors have contributed to the rise of
biotech acquisitions in the pharmaceutical industry. One significant factor is the growing complexity of drug development, particularly in areas such as
oncology and rare diseases, where targeted therapies and personalized medicine are becoming increasingly prevalent. Biotech companies, often specializing in these areas, possess valuable expertise and assets that can complement the capabilities of larger pharmaceutical firms.
Moreover, the patent cliff—the expiration of patents on blockbuster drugs—has pressured pharmaceutical companies to replenish their pipelines with innovative new therapies. Acquiring biotech companies with promising drug candidates offers a strategic way to mitigate the impact of patent expirations and maintain a competitive edge in the market.
https://worldofdtcmarketing.com/the-shifting-landscape-of-pharma-investment-acquiring-biotech-companies-over-research/